The compensation and personal wealth rankings of pharmaceutical chief executive officers feature prominent leaders managing the world's most valuable healthcare corporations. Executives heading high-growth pharmaceutical giants—such as David Ricks of Eli Lilly or leaders of major international drug development empires—frequently command multi-million dollar annual compensation packages heavily weighted in stock awards tied to record-breaking market valuations and blockbuster drug successes. Meanwhile, billionaire founders and majority stakeholders of major generic and proprietary pharmaceutical firms, such as Dilip Shanghvi of Sun Pharma, often hold substantial individual net worth figures derived directly from their corporate ownership stakes.